Abstract
The Treaty of the European Union (EU) strengthened the role of EU as an arena for and an actor in development of European drug policy. The article describes the judicial, political and organisational conditions for a Europeification of the drug policies of the Member States. The three pillars of the Treaty separate the policy areas into sectors with different governing principles and different potentials for harmonisation. Furthermore the article is focusing on the increasing local differences in national drug policies. As long as the European Union's competencies in law enforcement and public health policies are weak, these differences most likely will increase rather than move toward harmonisation. In the sector dealing with drug issues, national governments lose influence due to the increase of power at local level and European level. In spite of the limitations of the formal competencies in most sectors, an important institutionalisation of the field has taken place through establishment of EUROPOL, the European Drug Monitoring Centre, growth of the Commission's own expertise and the adoption of some Directives on drug-related issues.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.